Track the 셀트리온 share price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares are quoted on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 셀트리온 has published 29 reports. Market capitalisation: €41,622.9bn. The latest transaction was disclosed on 10 July 2026 (Purchase). Among the most active insiders: 장소용. The full history is openly available.
28
Insider Decl.
n/a
Thresholds
€714,238
24 ops.
Buy Volume
€366,075
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 셀트리온 Buy (bullish), based on 24 analysts. Average price target: ₩265,216.
36Σ signal
Buys €714,238€366,075 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 15,536 of 28,200 companies
49.1
score / 100
Value
33
Quality
65
FCF yld0.7%
Earn yld2.3%
EV/EBITDA32.6x
ROE7.3%
Gross mgn59%
Net mgn25%
Debt/EBITDA2.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
2,173 shares@ ₩139,147.000.0000% mcap100.0% of flowShareKRXDART:20260430001734
25 of 29 declarations
About 셀트리온
Celltrion is a South Korean company focused on the development and manufacturing of biosimilar drugs and biological therapies. It is listed on the Korea Exchange, XKRX.